Agenparl
Agenparl English Diritto & Giustizia Salute Social Network

ORPHAN DESIGNATION: HUMAN MONOCLONAL IGG2 ANTIBODY AGAINST TISSUE FACTOR PATHWAY INHIBITOR, TREATMENT OF HAEMOPHILIA A, , WITHDRAWN

(AGENPARL) – LONDON (UNITED KINGDOM), gio 26 marzo 2020

At the time of designation, medicines containing factor VIII were authorised in the EU for the treatment of haemophilia A, to replace the missing protein. However, factor VIII medicines did not work in some patients with haemophilia A because the immune system (the body’s natural defences) can produce ‘inhibitors’ (antibodies) against factor VIII which stop the factor VIII medicine from working. In these cases, other treatments needed to be used, such as factor VIIa (the activated form of factor VII, another protein involved in blood clotting), either alone or as part of a combination treatment.

The sponsor has provided sufficient information to show that this medicine might be of significant benefit for patients with haemophilia A because results from early studies showed that the medicine works in patients who have developed inhibitors to authorised treatments. In addition, studies in experimental models suggest that the medicine may be safer than some authorised treatments, because it lowers the risk of clots in blood vessels.

These assumptions will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.

Fonte/Source: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3181979

Related posts

QATARI GERMAN FOR MEDICAL POSTPONES ITS 2019 ORDINARY AND EXTRAORDINARY GENERAL ASSEMBLY MEETING

Redazione

DA’S ALPAS COVID-19 DISTRIBUTES VEGETABLE SEEDS

Redazione

TAGALOG NEWS: LIMA NA HEALTH WORKERS KABILANG SA 14 KASO NG COVID-19 SA CAGAYAN VALLEY

Redazione

: WHOLESALE AND RETAIL TRADE SALES STATISTICS, 6TH PERIOD 2019

Redazione

: AIR TRANSPORT, Q1 2020

Redazione

Для суворовцев Ульяновского гвардейского военного училища проведен цикл бесед-презентаций о героях Великой Отечественной войны гг.

Redazione

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More